Tags : Grifols

Insights+: COVID-19 Healthcare News Monthly Updates – October 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19). The outbreak of the respiratory disease was first detected […]Read More

Grifols to Acquire Remaining Stake of Alkahest for ~$146M

Shots: Grifols to acquire the remaining stock of Alkahest for a total value of $146M. The transaction is expected to be close in H1’21 The acquisition will enhance discovery, research, development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome Alkahest has developed a map of the human […]Read More

Top 20 Diagnostics Companies Based on 2019 Revenue

Diagnostics has emerged as one of the largest and fastest-growing segments with evolving diseases. The segment has played a vital role in diagnosing growing and ageing global population with increasing health expenditure and more prevalent lifestyle ailments including obesity, cancer, and cardiovascular diseases. Our team at PharmaShots has compiled a list of top 20 diagnostics […]Read More

Top 20 Diagnostics Companies Based On 2018 Revenue

With the era of growing diseases, Diagnostics have played a vital role in diagnosing multiple diseases and disorders. The healthcare system is changing, with a greater focus on value, reducing errors and giving more cost-effective care and treatments. The Diagnostic ledger has not changed much in comparison to 2017. Roche Diagnostics holds to be at […]Read More

Grifols’ Xembify (20% SC Immunoglobulin) Receives FDA’s Approval for the

Shots: The approval of Xembify reflects Grifols’ commitment to R+D+i and innovation which enables the company to develop new therapies and enhances its Bioscience Division’s product portfolio Grifol is working with regulatory authorities to seek approval in Canada, Europe and other global markets and plans to launch the Xembify in the US in Q4’19 Xembify is […]Read More